2018
DOI: 10.3390/ijms20010032
|View full text |Cite
|
Sign up to set email alerts
|

Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells

Abstract: Studies, including ours, have shown that pro-oxidative stressors, such as chemotherapeutic agents, generate oxidized lipids with agonistic platelet-activating factor (PAF) activity. Importantly, recent reports have implicated that these PAF-agonists are transported extracellularly via microvesicle particles (MVPs). While the role of PAF-receptor (PAF-R) has been implicated in mediating chemotherapy effects, its significance in chemotherapy-mediated MVP release in pancreatic cancer has not been studied. The cur… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
58
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 19 publications
(59 citation statements)
references
References 41 publications
1
58
0
Order By: Relevance
“…Among the altered processes in C5a-treated neutrophils, we found MV- relevant processes, such as catabolic and metabolic processes of glycosyl- and glyco-lipids, phospholipids and ceramids as well as activation and regulation of small GTPases ( Supplemental Table 1 ). Further MV-relevant changes in pathways involve cytoskeleton-based processes ( 31 ), cell shape changes, and MAPK activity ( 32 ) ( Supplemental Table 1 ).…”
Section: Resultsmentioning
confidence: 99%
“…Among the altered processes in C5a-treated neutrophils, we found MV- relevant processes, such as catabolic and metabolic processes of glycosyl- and glyco-lipids, phospholipids and ceramids as well as activation and regulation of small GTPases ( Supplemental Table 1 ). Further MV-relevant changes in pathways involve cytoskeleton-based processes ( 31 ), cell shape changes, and MAPK activity ( 32 ) ( Supplemental Table 1 ).…”
Section: Resultsmentioning
confidence: 99%
“…However, the role of the PAFR signaling in modulating targeted therapy effects in lung cancer models has not been studied. Given that these PAF agonists are metabolically labile and upon generation get readily metabolized by PAF-AH, our recent studies have defined the critical roles of a subpopulation of extracellular vesicles known as microvesicles or microvesicle particles as a novel mechanism by which these potent lipids are not only protected but circulated to exert local as well as delayed systemic effects [ 34 , 35 , 36 ].…”
Section: Introductionmentioning
confidence: 99%
“…PRAS40 downregulated Akt, downstream of TGF-β, and mediated antagonistic effects against exosome secretion and chemoresistance in breast and lung cancer cells [ 123 ]. WEB2086, a platelet-activating factor receptor (PAFR) antagonist, was shown to reduce gemcitabine-induced exosome release in PAFR-positive pancreatic cancer cells [ 124 ]. Other exosome extrusion inhibitors, such as chloramidine, bisindolylmaleimide-I, imipramine, d-pantethine, and calpeptin, and calcium chelators, such as ethylene glycol bis (2-aminoethyl ether) tetra-acetic acid, increased responsiveness toward 5-FU in prostate and BC cells [ 125 ].…”
Section: Strategies Against Tumor-derived Exosomesmentioning
confidence: 99%